Drug Approval | February 05, 2026
Strides Pharma Inc receives USFDA closure report for Chestnut Ridge formulations facility
Inspection included drug device combinations covering our recent filing in nasal sprays domain
Inspection included drug device combinations covering our recent filing in nasal sprays domain
These observations are procedural in nature and the company does not anticipate any impact on supply of its commercial products
USFDA determines Sun Pharma's Baska facility inspection classification as OAI
The inspection concluded with one minor observation in Form 483
The company will respond to the US FDA within the stipulated timelines
Ipca Laboratories receives three observations from USFDA for API facility at Tarapur
The Unit is approved by major regulators like EMA, Europe; Health Canada, Anvisa, Brazil and TGA, Australia
The said inspection concluded with Zero Form 483 observation
The inspection concluded with zero form 483 observations
The U.S. FDA issued a Form 483 with five observations
Subscribe To Our Newsletter & Stay Updated
